Top

Molecular Cancer

Published in:

Open Access 01-12-2014 | Research

HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma

Authors: Banzhou Pan, Dongqin Chen, Jiayuan Huang, Rui Wang, Bing Feng, Haizhu Song, Longbang Chen

Published in: Molecular Cancer | Issue 1/2014

Abstract

Background

Docetaxel resistance remains a major obstacle in the treatment of non-small cell lung cancer (NSCLC). High-mobility group box 1 (HMGB1) has been shown to promote autophagy protection in response to antitumor therapy, but the exact molecular mechanism underlying HMGB1-mediated autophagy has not been clearly defined.

Methods

Lung adenocarcinoma (LAD) cells were transfected with pcDNA3.1-HMGB1 or HMGB1 shRNA, followed by docetaxel treatment. Cell viability and proliferation were tested by MTT assay and colony formation assay, respectively. Annexin V flow cytometric analysis and western blot analysis of activated caspase3 and cleaved PARP were used to evaluate apoptosis, while immunofluorescence microscopy and transmission electron microscopy were applied to assess autophagy activity. The formation of the Beclin-1-PI3K-III complex was examined by immunoprecipitation analysis. NOD/SCID mice were inoculated with docetaxel-resistant SPC-A1/DTX cells transfected with control or HMGB1 shRNA.

Results

HMGB1 translocated from the nucleus to the cytoplasm in LAD cells exposed to docetaxel and acted as a positive regulator of autophagy, which inhibited apoptosis and increased drug resistance. Suppression of HMGB1 restored the sensitivity of LAD cells to docetaxel both in vivo and in vitro. Mechanistic investigation revealed that HMGB1 promoted the formation of the Beclin-1-PI3K-III complex through activating the mitogen-activated protein kinase (MEK)-extracellular signal-regulated kinase (ERK) signaling pathway, thereby regulating autophagosome formation.

Conclusions

Our results demonstrated that HMGB1-regulated autophagy is a significant contributor to docetaxel resistance in LAD cells. Suppression of HMGB1 or limiting HMGB1 cytosolic translocation diminished autophagic protection in response to docetaxel in LAD cells.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107CrossRefPubMed

Gettinger S, Lynch T: A decade of advances in treatment for advanced non-small cell lung cancer. Clin Chest Med. 2011, 32: 839-851. 10.1016/j.ccm.2011.08.017CrossRefPubMed

Uygun K, Aksu G, Cicin I, Karagol H, Kocak Z, Fayda M, Binici A, Uzunoglu F: The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma. Med Oncol. 2008, 25: 408-414. 10.1007/s12032-008-9055-1CrossRefPubMed

Kondo Y, Kanzawa T, Sawaya R, Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005, 5: 726-734. 10.1038/nrc1692CrossRefPubMed

Mizushima N, Yoshimori T, Levine B: Methods in mammalian autophagy research. Cell. 2010, 140: 313-326. 10.1016/j.cell.2010.01.028PubMedCentralCrossRefPubMed

Dikic I, Johansen T, Kirkin V: Selective autophagy in cancer development and therapy. Cancer Res. 2010, 70: 3431-3434. 10.1158/0008-5472.CAN-09-4027CrossRefPubMed

Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, Zhang L, Manfredi JJ, Zeh HJ, Li L, Lotze MT, Tang D: p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res. 2012, 72: 1996-2005. 10.1158/0008-5472.CAN-11-2291PubMedCentralCrossRefPubMed

Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, Zeh HJ, Lotze MT: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 2010, 29: 5299-5310. 10.1038/onc.2010.261PubMedCentralCrossRefPubMed

Bell CW, Jiang W, Reich CF, Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol. 2006, 291: C1318-C1325.CrossRefPubMed

10.

Leblanc PM, Doggett TA, Choi J, Hancock MA, Durocher Y, Frank F, Nagar B, Ferguson TA, Saleh M: An immunogenic peptide in the a-box of HMGB1 protein reverses apoptosis-induced tolerance through RAGE receptor. J Biol Chem. 2014, 289: 7777-7786. 10.1074/jbc.M113.541474PubMedCentralCrossRefPubMed

11.

Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, Zornig M: HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 2003, 17: 1295-1297.PubMed

12.

Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C, Bullerdiek J: Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma. 2008, 49: 1184-1189. 10.1080/10428190802064909CrossRefPubMed

13.

Lee H, Park M, Shin N, Kim G, Kim YG, Shin JS, Kim H: High mobility group box-1 is phosphorylated by protein kinase C zeta and secreted in colon cancer cells. Biochem Biophys Res Commun. 2012, 424: 321-326. 10.1016/j.bbrc.2012.06.116CrossRefPubMed

14.

Zhan Z, Li Q, Wu P, Ye Y, Tseng HY, Zhang L, Zhang XD: Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1. Autophagy. 2012, 8: 109-121. 10.4161/auto.8.1.18319CrossRefPubMed

15.

Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Avadie N, Anantharam V: Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012, 8: 445-544. 10.4161/auto.19496PubMedCentralCrossRefPubMed

16.

Wallington-Beddoe CT, Hewson J, Bradstock KF, Bendall LJ: FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy. 2011, 7: 707-715. 10.4161/auto.7.7.15154CrossRefPubMed

17.

Slee EA, Zhu H, Chow SC, MacFarlane M, Nicholson DW, Cohen GM: Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32. Biochem J. 1996, 315 (Pt 1): 21-24.PubMedCentralCrossRefPubMed

18.

Ling YH, Aracil M, Zou Y, Yuan Z, Lu B, Jimeno J, Cuervo AM, Perez-Soler R: PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase. Clin Cancer Res. 2011, 17: 5353-5366. 10.1158/1078-0432.CCR-10-1948CrossRefPubMed

19.

Wang M, Yu T, Zhu C, Sun H, Qiu Y, Zhu X, Li J: Resveratrol triggers protective autophagy through the ceramide/Akt/mTOR pathway in melanoma B16 cells. Nutr Cancer. 2014, 66: 435-440. 10.1080/01635581.2013.878738CrossRefPubMed

20.

Gulati P, Thomas G: Nutrient sensing in the mTOR/S6K1 signalling pathway. Biochem Soc Trans. 2007, 35: 236-238. 10.1042/BST0350236CrossRefPubMed

21.

Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell. 2006, 124: 471-484. 10.1016/j.cell.2006.01.016CrossRefPubMed

22.

Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S: Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005, 65: 3336-3346.PubMed

23.

Yang Z, Klionsky DJ: Eaten alive: a history of macroautophagy. Nat Cell Biol. 2010, 12: 814-822. 10.1038/ncb0910-814PubMedCentralCrossRefPubMed

24.

He C, Klionsky DJ: Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009, 43: 67-93. 10.1146/annurev-genet-102808-114910PubMedCentralCrossRefPubMed

25.

Foo J, Michor F: Evolution of acquired resistance to anti-cancer therapy. J Theor Biol. 2014, 355C: 10-20.CrossRef

26.

Lai PF, Cheng CF, Lin H, Tseng TL, Chen HH, Chen SH: ATF3 protects against LPS-induced inflammation in mice via inhibiting HMGB1 expression. Evid Based Complement Altern Med. 2013, 2013: 716481-

27.

Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, Bierhaus A, Lotze MT, Zeh HJ: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. 2010, 17: 666-676. 10.1038/cdd.2009.149PubMedCentralCrossRefPubMed

28.

Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ, Lotze MT: Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010, 190: 881-892. 10.1083/jcb.200911078PubMedCentralCrossRefPubMed

29.

Perez-Carrion MD, Cena V: Knocking down HMGB1 using dendrimer-delivered siRNA unveils its key role in nmda-induced autophagy in rat cortical neurons. Pharm Res. 2013, 30: 2584-2595. 10.1007/s11095-013-1049-9CrossRefPubMed

30.

Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013CrossRefPubMed

31.

Yang L, Yu Y, Kang R, Yang M, Xie M, Wang Z, Tang D, Zhao M, Liu L, Zhang H, Cao L: Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells. Leuk Lymphoma. 2012, 53: 315-322. 10.3109/10428194.2011.616962CrossRefPubMed

32.

He Q, Liang CH, Lippard SJ: Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A. 2000, 97: 5768-5772. 10.1073/pnas.100108697PubMedCentralCrossRefPubMed

33.

Song B, Song WG, Li ZJ, Xu ZF, Wang XW, Wang CX, Liu J: Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells. Cell Biochem Funct. 2011, 30: 11-17.CrossRefPubMed

34.

Zhuang ZY, Xu H, Clapham DE, Ji RR: Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J Neurosci. 2004, 24: 8300-8309. 10.1523/JNEUROSCI.2893-04.2004CrossRefPubMed

35.

Watson AL, Anderson LK, Greeley AD, Keng VW, Rahrmann EP, Halfond AL, Powell NM, Collins MH, Rizvi T, Moertel CL, Ratner N, Largaespada DA: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Oncotarget. 2014, 30: 1502-1514.CrossRef

36.

Kang R, Zeh HJ, Lotze MT, Tang D: The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011, 18: 571-580. 10.1038/cdd.2010.191PubMedCentralCrossRefPubMed

37.

Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D: HMGB1 promotes drug resistance in osteosarcoma. Cancer Res. 2012, 72: 230-238. 10.1158/0008-5472.CAN-11-2001CrossRefPubMed

38.

Tsang WP, Kwok TT: The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis. 2009, 30: 953-959. 10.1093/carcin/bgp094CrossRefPubMed

39.

Liu P, Chen L, Huang X: The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother Radiopharm. 2009, 24: 91-98. 10.1089/cbr.2008.0533CrossRefPubMed

40.

Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao Y: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res. 2005, 11: 4646-4652. 10.1158/1078-0432.CCR-04-2013CrossRefPubMed

41.

Kyrylkova K, Kyryachenko S, Leid M, Kioussi C: Detection of apoptosis by TUNEL assay. Methods Mol Biol. 2012, 887: 41-47. 10.1007/978-1-61779-860-3_5CrossRefPubMed

Title: HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma
Authors: Banzhou Pan
Dongqin Chen
Jiayuan Huang
Rui Wang
Bing Feng
Haizhu Song
Longbang Chen
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-13-165

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer

miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells

ADAM17 mediates OSCC development in an orthotopic murine model

A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma

miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer

Loss of vinculin and membrane-bound β-catenin promotes metastasis and predicts poor prognosis in colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer